Vectibix (Panitumumab Vials) 20 MG / 20 ML

Panitumumab is a monoclonal antibody used to treat certain cancers by targeting EGFR. This 20 MG / 20 ML vial form is designed for intravenous administration under medical supervision. Store between 2-8°C to maintain stability. Always consult a healthcare professional for proper use.

Strength

20 MG / 20 ML

Pack Size

Storage

2-8°

Manufacturer / TM Owner

AMGEN İLAÇ

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Panitumumab is primarily used in the treatment of metastatic colorectal cancer in patients with wild-type KRAS tumors. It may be prescribed alongside chemotherapy for improved outcomes. This medication is often recommended when other treatments have not been effective. Patients should discuss their specific diagnosis with their oncologist.

Side Effects

Panitumumab works by binding to EGFR on cancer cells, helping to slow or stop their growth. Common effects include skin reactions, fatigue, and gastrointestinal discomfort. Some patients may experience changes in nail or hair texture. These effects vary by individual and should be monitored by a healthcare provider.

Precautions & Warnings

This medication should only be handled and administered by trained medical professionals. Store vials refrigerated between 2-8°C and protect from light. Avoid shaking the vial to prevent foaming. Patients should report any unusual symptoms to their doctor immediately. Pregnant or breastfeeding individuals should discuss risks with their healthcare provider.

Avoid Interactions

Panitumumab may interact with other medications that affect the immune system, such as corticosteroids or immunosuppressants. Combining it with certain chemotherapy drugs could increase side effects. Alcohol use should be limited, as it may worsen fatigue or gastrointestinal issues. Always inform your doctor about all medications you are taking.

Frequently Asked Questions

Panitumumab is used to treat metastatic colorectal cancer in patients with wild-type KRAS tumors.

Panitumumab is given as an intravenous infusion by a healthcare professional.

Common side effects include skin reactions, fatigue, and gastrointestinal discomfort.

No, Panitumumab should be stored refrigerated between 2-8°C.

Yes, it may interact with immunosuppressants, corticosteroids, and certain chemotherapy drugs.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.